AKTing on XPO1 inhibition in AML

被引：0

作者：

Goellner, Stefanie ^{[1
]}

Mueller-Tidow, Carsten ^{[1
,2
,3
,4
]}

机构：

[1] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany

[2] European Mol Biol Lab, Mol Med Partnership Unit, Heidelberg, Germany

[3] Heidelberg Univ, Heidelberg, Germany

[4] Natl Ctr Tumor Dis, Heidelberg, Germany

来源：

NATURE CANCER | 2022年 / 3卷 / 07期

关键词：

NUCLEAR EXPORT; C/EBP-BETA; EXPRESSION; CRM1;

D O I：

10.1038/s43018-022-00395-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, purinergic receptor-mediated AKT activation potentiates its anti-leukemic activity.

引用

页码：787 / 789

页数：3

共 50 条

[1] AKTing on XPO1 inhibition in AML
Stefanie Göllner
Carsten Müller-Tidow
Nature Cancer, 2022, 3 : 787 - 789
[2] Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
Pianigiani, Giulia
Gagliardi, Andrea
Mezzasoma, Federica
Rocchio, Francesca
Tini, Valentina
Bigerna, Barbara
Sportoletti, Paolo
Caruso, Simona
Marra, Andrea
Peruzzi, Sara
Petito, Eleonora
Spinozzi, Giulio
Shacham, Sharon
Landesman, Yosef
Quintarelli, Concetta
Gresele, Paolo
Locatelli, Franco
Brunetti, Lorenzo
Martelli, Maria Paola
Falini, Brunangelo
BLOOD ADVANCES, 2022, 6 (22) : 5938 - 5949
[3] Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML)
Rettig, Michael P.
Holt, Matthew
Prior, Julie
Shacham, Sharon
Kauffman, Michael
McCauley, Dilara
Dipersio, John F.
BLOOD, 2013, 122 (21)
[4] Effect of XPO1 inhibition on colorectal cancer tumorigenesis
Evans, Andrew E.
Dixon, Dan A.
CANCER RESEARCH, 2024, 84 (06)
[5] Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors
Conforti, Fabio
Zhang, Xu
Rao, Guanhua
De Pas, Tommaso
Yonemori, Yoko
Antonio Rodriguez, Jose
McCutcheon, Justine N.
Rahhal, Raneen
Alberobello, Anna T.
Wang, Yisong
Zhang, Yu-Wen
Guha, Udayan
Giaccone, Giuseppe
CANCER RESEARCH, 2017, 77 (20) : 5614 - 5627
[6] Prolonged XPO1 Inhibition Is Essential for Optimal Anti-Leukemic Activity in NPM1-Mutated AML
Pianigiani, Giulia
Gagliardi, Andrea
Tini, Valentina
Bigerna, Barbara
Caruso, Simona
Marra, Andrea
Shacham, Sharon
Landesman, Yosef
Quintarelli, Concetta
Locatelli, Franco
Martelli, Maria Paola
Falini, Brunangelo
Brunetti, Lorenzo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S212 - S213
[7] Preclinical evaluation of XPO1 inhibition in Wilms tumors.
Ortiz, Michael Vincent
Siddiquee, Armaan
You, Daoqi
Mundi, Prabhjot Singh
Marks, Lianna Q.
Guillan, Kristina
Diolaiti, Daniel
Aburi, Mahalaxmi
Califano, Andrea
Dela Cruz, Filemon S.
Kung, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Protein biomarkers for response to XPO1 inhibition in haematologic malignancies
Totiger, Tulasigeri M.
Chaudhry, Sana
Musi, Elgilda
Afaghani, Jumana
Montoya, Skye
Owusu-Ansah, Frank
Lee, Stanley
Schwartz, Gary
Klimek, Virginia
Taylor, Justin
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2023, 27 (04) : 587 - 590
[9] Strahlensensibilität durch Inhibition von XPO1 in Zelllinien kolorektaler Karzinome gesteigertRadiation response enhanced by inhibition of XPO1 in preclinical rectal cancer models
Moritz von Fallois
Reinhard Depping
Strahlentherapie und Onkologie, 2016, 192 : 961 - 962
[10] XPO1 INHIBITION USING SELINEXOR SYNERGIZES WITH CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA (AML) BY TARGETING DNA REPAIR GENES
Yu, X.
Kashyap, T.
Ranganathan, P.
Bhatnagar, B.
Shacham, S.
Kauffman, M.
Blum, W.
Landesman, Y.
Garzon, R.
HAEMATOLOGICA, 2015, 100 : 212 - 212

← 1 2 3 4 5 →